Why Progyny stock is back on investors’ radar

Progyny (PGNY) is drawing fresh attention after reporting fourth quarter and full year 2025 earnings, pairing that update with a completed share buyback, cautious 2026 revenue guidance, and a new ESOP related shelf registration.

Progyny’s recent earnings update, buyback completion, and ESOP related shelf registration have arrived against a weak share price backdrop, with a 30 day share price return of 16.58% decline and a 1 year total shareholder return of 7.62% decline. This suggests near term momentum has faded even as investors reassess long term prospects in fertility and women’s health benefits.

If this news has you thinking about where else growth and benefit driven models might show up, it could be a good time to look at 32 healthcare AI stocks as potential ideas beyond Progyny.

So with shares weak over 1 year even as Progyny posts higher annual revenue and net income and completes a sizeable buyback, is the stock being overlooked, or is the cautious 2026 outlook already fully priced in?

Most Popular Narrative: 40.8% Undervalued

Progyny’s most followed narrative pegs fair value at $30.91 per share versus the last close of $18.31, framing a wide gap that rests on long term earnings and revenue assumptions.

The continued shift in demographics, specifically delayed family formation and rising maternal age, supports an expanding addressable market for fertility benefits. This trend should drive increased client acquisition and member utilization, fueling growth in covered lives and recurring revenue.

Curious how this story adds up to that higher price? The narrative leans heavily on steady revenue expansion, higher margins, and a richer earnings profile than today.

Result: Fair Value of $30.91 (UNDERVALUED)

However, you still need to weigh employer cost cutting and potential regulatory shifts around reproductive health, either of which could challenge the bullish long term narrative.

Another angle on what the market is paying for Progyny

That $30.91 fair value points to undervaluation, but the current P/E of 25.6x tells a different story. It sits above the US Healthcare industry at 22.4x, the peer average at 22.2x, and even the 21.9x fair ratio our model suggests the market could move toward. Is the earnings multiple already reflecting more optimism than the cash flow work implies?

Next Steps

If this combination of caution and optimism feels unclear to you, do not wait too long to review the underlying numbers and form your own view, starting with 3 key rewards.

Looking for more investment ideas?

If Progyny has you rethinking your watchlist, use this moment to refresh your research and widen your options with a few focused stock ideas.

Missing these screens could mean passing on companies that better match your risk, income, or growth preferences.

• Target potential mispricing by scanning companies our screener flags as 50 high quality undervalued stocks before other investors catch on.
• Build a steadier income stream by reviewing businesses in our hand picked list of 16 dividend fortresses that prioritize regular payouts.
• Lower your stress level by focusing on companies identified in our 66 resilient stocks with low risk scores that pair financial resilience with measured risk profiles.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.